{
    "symbol": "VIVE",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-12 21:06:01",
    "content": " This includes remarks about the corporation's cost, timing, progress and results of its clinical trials, including the initiation progress of and results from our PURSUIT trial and whether the clinical trial will support the intended uses for treatment of Stress Urinary Incontinence or SUI in the United States, fluctuation of global market economic conditions, impact of the novel coronavirus on clinical development, regulatory review and clearances, manufacturing system placements and utilization projections, expectations, plans, beliefs and prospects. Through the remainder of 2022, we intend to successfully complete our PURSUIT trial expand our installed base in the US and Asia Pacific regions, with core medical specialties, support our existing customers to drive increased treatment tip utilization and sales, and to continue the financial efficiencies we have achieved."
}